Houttuynia cordata injection
Function and Efficacy
(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.
Ingredients
Fresh Houttuynia cordata, auxiliary ingredients are sodium chloride and polysorbate-.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Sodium chlorideExcipients |
(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg. More |
7647-14-5 | 43 | |
| Tween 85Excipients |
(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg. More |
9005-70-3 | 0 |
Usage and Dosage
1. Intramuscular injection: 2-4 ml at a time, 4-6 ml per day; 2. Intravenous drip: 20-100 ml at a time, diluted with 5-10% glucose injection solution, or follow the doctor's advice.
Adverse Reactions
1. This product may cause severe allergic reactions: anaphylactic shock, pulmonary edema, laryngeal edema, allergic purpura, bullous epidermolysis drug eruption, exfoliative dermatitis, severe erythema multiforme, etc. 2. Other adverse reactions may also be seen. Skin and mucous membrane manifestations: skin flushing, itching, urticaria, maculopapular rash and angioneurotic edema, etc. Symptoms of respiratory obstruction: chest tightness, shortness of breath, wheezing, breath holding, cyanosis, dyspnea, etc. Digestive system manifestations: nausea, vomiting, abdominal pain, diarrhea, etc. Circulatory system manifestations: palpitations, sweating, pale complexion, cold limbs, cyanosis, etc. Changes in consciousness: irritability, dizziness, headache, confusion, etc. 3. Intramuscular injection may cause local pain.
Precautions
(1) Those who are allergic to this product are prohibited from using it. (2) Pregnant women and children are prohibited from using it.
Drug Interactions
There is no information on the interaction of this product with other drugs.
Storage
Store in a cool, dark place. Valid for 2 years.
Packaging Specification
2ml per bottle
Manufacturer
Guangdong Xinfeng Pharmaceutical Co., Ltd.
-
Founded in:
1995-09-28 -
Address:
Hongbo Industrial Zone, Boluo County -
Tax NO.:
914413001961374115 -
Registered Funds:
102 million yuan -
Website:
-
Email: